loading page

The Characteristics of Peripheral Blood Mononuclear Cells in Takayasu Arteritis by Single Cell RNA Sequencing
  • +6
  • Qing Gao,
  • Jinge Yu,
  • Zuoguan Chen,
  • Yongpeng Diao,
  • Yuqing Miao,
  • Jinfeng Yin,
  • Junnan Jia,
  • Weimin Li,
  • Yongjun Li
Qing Gao
Beijing Hospital
Author Profile
Jinge Yu
Renmin University of China
Author Profile
Zuoguan Chen
Beijing Hospital
Author Profile
Yongpeng Diao
Beijing Hospital
Author Profile
Yuqing Miao
Beijing Hospital
Author Profile
Jinfeng Yin
Capital Medical University
Author Profile
Junnan Jia
Capital Medical University
Author Profile
Weimin Li
Capital Medical University
Author Profile
Yongjun Li
Beijing Hospital
Author Profile

Abstract

Objectives Takayasu Arteritis (TA) is a rare non-specific vascular inflammation and has deleterious effects on patients’ health. Recent studies have advanced in TA diagnosis and treatment, but the research on the immune cell atlas of peripheral blood is still less. For this purpose, we performed single-cell RNA sequencing (scRNA-seq) to analyze the inflammatory cell types and cell markers in TA patients’ Peripheral blood mononuclear cells (PBMCs). Methods 4 TA patients and 4 health controls were enrolled in our study from 2019.10 to 2020.5. Their PBMCs samples were collected and performed scRNA-seq. We used Seurat package (v.3.2.2) in R studio (v.3.5.3) for data analysis, and 2 tests were applied for comparing the composition ratio of each cell type by SPSS 20.0. Results CD14+ monocytes, GZMB+ NKT cells, CD56dim CD16+ NK cells, and naive B cells were significantly increased in TA patients as compared to healthy controls and the expression of THBS1, CD163, AREG, IFITM1, TXNIP, and IGHGs was elevated in the peripheral blood of TA patients. Conclusion Except CD4+ T cells, monocytes, NK cells, NKT cells, B cells also play an important role in TA pathogenesis. The elevated markers have different functions in different types of PBMCs, and they can be used as potential diagnostic markers for TA diagnosis.

Peer review status:UNDER REVIEW

24 Jan 2021Submitted to Clinical & Experimental Immunology
27 Jan 2021Assigned to Editor
27 Jan 2021Submission Checks Completed
28 Jan 2021Reviewer(s) Assigned
17 Feb 2021Review(s) Completed, Editorial Evaluation Pending
17 Feb 2021Editorial Decision: Revise Major
08 Jun 20211st Revision Received
09 Jun 2021Reviewer(s) Assigned